Home
Portfolio
Strategy
Team
News
Contact
Investor Login
Home
Portfolio
Strategy
Team
News
Contact
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
Read Article
News
2021
2020
Archive
May 16, 2009
ACHAOGEN DATA SHOW RAPID RISE IN RATES OF RESISTANCE TO CURRENT ANTIBIOTICS; ILLUSTRATE GLOBAL NEED FOR NEW, WELL-TOLERATED AGENTS TO ADDRESS VARIED MECHANISMS OF RESISTANCE
May 13, 2009
SYNOSIA THERAPEUTICS BEGINS PHASE I TRIAL OF A NEW GENERATION TREATMENT FOR COGNITIVE IMPAIRMENT
May 1, 2009
PULMATRIX ANNOUNCES PH 1B/2A CLINICAL TRIAL OF NOVEL ICALM THERAPY FOR FLU
March 10, 2009
SYNOSIA ANNOUNCES SECOND AGREEMENT WITH ROCHE
March 9, 2009
IGENICA APPOINTS DR. MIKE ROTHE AS CEO AFTER CLOSING SERIES A FINANCING
March 3, 2009
ACHAOGEN SIGNS $26.6 MILLION CONTRACT WITH NIAID FOR DEVELOPMENT OF NEW THERAPY TO TREAT RESISTANT STRAINS OF NIAID CATEGORY A AND B PRIORITY PATHOGENS
February 24, 2009
PEARL THERAPEUTICS SECURES $8 MILLION IN DEBT FINANCING
February 9, 2009
ENTREMED PRESENTS INITIAL CLINICAL RESULTS FOR ENMD-2076
February 9, 2009
BIOTECHS BEFRIEND NON-DILUTIVE FUNDS
February 3, 2009
ACHAOGEN INITIATES PHASE 1 TRIAL OF ACHN-490 FOR TREATMENT OF MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS
« Previous Page
1
…
73
74
75
76
Next Page »
